Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial
Open Access
- 6 March 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (5) , e007475
Abstract
Background: Although diastolic blood pressure ( DBP ) is independently associated with an increased risk of adverse cardiovascular outcomes in the general population, it is unclear if a similar relationship exists in patients with heart failure with preserved ejection fraction. Methods and Results: This analysis included 1703 (mean age, 72±10 years; 50% men; 78% white) patients with heart failure with preserved ejection fraction enrolled in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial from the Americas who were treated for hypertension. Multivariable Cox regression was used to examine the risk of hospitalization for heart failure, death, and cardiovascular death associated with DBP . The relationship between hospitalization for heart failure and DBP was linear, with an increased risk observed with decreasing DBP values (≥90 mm Hg: referent; 80–89 mm Hg: hazard ratio [HR], 1.44; 95% confidence interval [CI], 0.85–2.44; 70–79 mm Hg: HR , 1.18; 95% CI , 0.69–2.01; 60–69 mm Hg: HR , 1.54; 95% CI , 0.90–2.63; P =0.0055 for trend). The associations of DBP with death (≥90 mm Hg: HR , 1.86; 95% CI , 1.12–3.06; 80–89 mm Hg: HR , 1.23; 95% CI , 0.89–1.70; 70–79 mm Hg: referent; 60–69 mm Hg: HR , 1.20; 95% CI , 0.90–1.59; <60 mm Hg: HR , 1.68; 95% CI , 1.21–2.33) and cardiovascular death (≥90 mm Hg: HR , 2.02; 95% CI , 1.10–3.71; 80–89 mm Hg: HR , 1.17; 95% CI , 0.77–1.79; 70–79 mm Hg: referent; 60–69 mm Hg: HR , 1.16; 95% CI , 0.80–1.70; <60 mm Hg: HR , 1.85; 95% CI , 1.21–2.82) were nonlinear, with a greater risk of each outcome observed with DBP values ≥90 and <60 mm Hg. Conclusions: DBP values ≥90 and <60 mm Hg are associated with a significant risk of adverse outcomes in patients with heart failure with preserved ejection fraction who are treated for hypertension. Further research is needed to determine optimal DBP targets to reduce the risk of adverse events in patients with heart failure with preserved ejection fraction.Keywords
This publication has 17 references indexed in Scilit:
- Phenotype-Specific Treatment of Heart Failure With Preserved Ejection FractionCirculation, 2016
- Predicting Heart Failure With Preserved and Reduced Ejection FractionCirculation: Heart Failure, 2016
- A Randomized Trial of Intensive versus Standard Blood-Pressure ControlNew England Journal of Medicine, 2015
- Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialCirculation, 2015
- Heart Failure With Preserved Ejection FractionCirculation Research, 2014
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist TrialCirculation: Heart Failure, 2013
- Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAmerican Heart Journal, 2011
- Dose‐response analyses using restricted cubic spline functions in public health researchStatistics in Medicine, 2010
- Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?Annals of Internal Medicine, 2006